Literature DB >> 21431896

Immunizations and risk of multiple sclerosis: systematic review and meta-analysis.

Mauricio F Farez1, Jorge Correale.   

Abstract

The role of vaccinations in risk of developing multiple sclerosis (MS) or in risk of relapse has not been well established. The aim of this study was to estimate the effect of immunizations on risk of developing MS in adults as well as in subsequent risk of relapse. Systematic search for publications in MEDLINE (1966-January 2011), EMBASE (1977-January 2011) and the Cochrane Central Register of Controlled Trials (CENTRAL) (1961-January 2011). Both randomized clinical trials and non-randomized studies addressing the effect of any Center for Diseases Control (CDC) recommended vaccine for children, adults or travelers and BCG on risk of MS or disease relapse were included. Two reviewers independently extracted information from articles selected using a predefined datasheet. No significant change in the risk of developing MS after vaccination was found for BCG (OR 0.96, 95% CI 0.69-1.34), Hepatitis B (OR 1.00, 95% CI 0.74-1.37), Influenza (OR 0.97, 95% CI 0.77-1.23), Measles-Mumps-Rubella (MMR) (OR 1.02, 95% CI 0.64-1.61), Polio (OR 0.87, 95% CI 0.61-1.25) and Typhoid fever (OR 1.05, 95% CI 0.72-1.53). We found decreased risk of developing MS for Diphtheria (OR 0.60, 95% CI 0.40-0.90) and Tetanus (OR 0.68, 95% CI 0.54-0.84). Influenza immunization was also associated with no change in risk of MS relapse (RR 1.24, 95% CI 0.89-1.72). Risk of developing multiple sclerosis remained unchanged after BCG, Hepatitis B, Influenza, MMR, Polio and Typhoid fever immunization, whereas diphtheria and tetanus vaccination may be associated with a decreased risk of MS. Further research is needed for the remaining vaccines.

Entities:  

Mesh:

Year:  2011        PMID: 21431896     DOI: 10.1007/s00415-011-5984-2

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  50 in total

1.  No increase in demyelinating diseases after hepatitis B vaccination.

Authors:  F Zipp; J G Weil; K M Einhäupl
Journal:  Nat Med       Date:  1999-09       Impact factor: 53.440

2.  The risk of relapses in multiple sclerosis during systemic infections.

Authors:  Jorge Correale; Marcela Fiol; Wendy Gilmore
Journal:  Neurology       Date:  2006-07-26       Impact factor: 9.910

Review 3.  Immunizations and autism: a review of the literature.

Authors:  Asif Doja; Wendy Roberts
Journal:  Can J Neurol Sci       Date:  2006-11       Impact factor: 2.104

4.  CNS demyelination and quadrivalent HPV vaccination.

Authors:  I Sutton; R Lahoria; Il Tan; P Clouston; Mh Barnett
Journal:  Mult Scler       Date:  2008-09-19       Impact factor: 6.312

5.  Influenza virus vaccination of patients with multiple sclerosis.

Authors:  F Mokhtarian; D Shirazian; L Morgante; A Miller; D Grob; E Lichstein
Journal:  Mult Scler       Date:  1997-08       Impact factor: 6.312

6.  Vaccinations and risk of central nervous system demyelinating diseases in adults.

Authors:  Frank DeStefano; Thomas Verstraeten; Lisa A Jackson; Catherine A Okoro; Patti Benson; Steven B Black; Henry R Shinefield; John P Mullooly; William Likosky; Robert T Chen
Journal:  Arch Neurol       Date:  2003-04

7.  Geographic variation of MS incidence in two prospective studies of US women.

Authors:  M A Hernán; M J Olek; A Ascherio
Journal:  Neurology       Date:  1999-11-10       Impact factor: 9.910

8.  Hepatitis B vaccination and first central nervous system demyelinating events: reanalysis of a case-control study using the self-controlled case series method.

Authors:  M N Hocine; C P Farrington; E Touzé; H J Whitaker; A Fourrier; T Moreau; P Tubert-Bitter
Journal:  Vaccine       Date:  2007-06-08       Impact factor: 3.641

Review 9.  The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?

Authors:  Howard L Weiner
Journal:  Ann Neurol       Date:  2009-03       Impact factor: 10.422

Review 10.  Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration.

Authors:  Jan P Vandenbroucke; Erik von Elm; Douglas G Altman; Peter C Gøtzsche; Cynthia D Mulrow; Stuart J Pocock; Charles Poole; James J Schlesselman; Matthias Egger
Journal:  PLoS Med       Date:  2007-10-16       Impact factor: 11.069

View more
  27 in total

Review 1.  Vaccination against infection in patients with multiple sclerosis.

Authors:  Micha Loebermann; Alexander Winkelmann; Hans-Peter Hartung; Hartmut Hengel; Emil C Reisinger; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2012-01-24       Impact factor: 42.937

Review 2.  Vaccination of healthcare workers: A review.

Authors:  Skerdi Haviari; Thomas Bénet; Mitra Saadatian-Elahi; Philippe André; Pierre Loulergue; Philippe Vanhems
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 3.  [Multiple sclerosis and hepatitis B vaccination : What does the verdict of the European Court of Justice on liability after vaccination mean?]

Authors:  M Löbermann; B Handorn; A Winkelmann; E C Reisinger; H P Hartung; U K Zettl
Journal:  Nervenarzt       Date:  2018-10       Impact factor: 1.214

Review 4.  Vaccines in Multiple Sclerosis.

Authors:  Eric M L Williamson; Salim Chahin; Joseph R Berger
Journal:  Curr Neurol Neurosci Rep       Date:  2016-04       Impact factor: 5.081

Review 5.  Current Immunological and Clinical Perspective on Vaccinations in Multiple Sclerosis Patients: Are They Safe after All?

Authors:  Shani Witman Tsur; Eli Adrian Zaher; Meydan Tsur; Karolina Kania; Alicja Kalinowska-Łyszczarz
Journal:  Int J Mol Sci       Date:  2021-04-08       Impact factor: 5.923

6.  Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease-modifying therapies.

Authors:  Christoph Metze; Alexander Winkelmann; Micha Loebermann; Michael Hecker; Brunhilde Schweiger; Emil Christian Reisinger; Uwe Klaus Zettl
Journal:  CNS Neurosci Ther       Date:  2018-07-25       Impact factor: 5.243

Review 7.  Viruses and multiple sclerosis.

Authors:  Jussi Oskari Virtanen; Steve Jacobson
Journal:  CNS Neurol Disord Drug Targets       Date:  2012-08       Impact factor: 4.388

Review 8.  Central nervous system demyelinating diseases and recombinant hepatitis B vaccination: a critical systematic review of scientific production.

Authors:  V Martínez-Sernández; A Figueiras
Journal:  J Neurol       Date:  2012-10-20       Impact factor: 4.849

9.  COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021.

Authors:  Anat Achiron; Mark Dolev; Shay Menascu; Daniela-Noa Zohar; Sapir Dreyer-Alster; Shmuel Miron; Emanuel Shirbint; David Magalashvili; Shlomo Flechter; Uri Givon; Diana Guber; Yael Stern; Michael Polliack; Rina Falb; Michael Gurevich
Journal:  Mult Scler       Date:  2021-04-15       Impact factor: 6.312

Review 10.  Vaccines and multiple sclerosis: a systematic review.

Authors:  Mia Topsøe Mailand; Jette Lautrup Frederiksen
Journal:  J Neurol       Date:  2016-09-07       Impact factor: 6.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.